Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 92Active not recruiting 55Completed 32Terminated 17Withdrawn 14Not yet recruiting 9Unknown 7Suspended 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 18Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × Interventional × X-Rays × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡